Drug Name:
AMEAL BP OTC
Generic Name and Formulations:
AmealPeptide (valyl-prolyl-proline, isoleucyl-prolyl-proline) 5mg per serving; caps or chewable tabs (citrus flavor); contains sodium 15mg/2 caps, 10mg/3 tabs; chew tabs contain phenylalanine.
Company:
Calpis USA, Inc.
Therapeutic Use:
Indications for AMEAL BP:
Dietary supplement to help maintain blood pressure in patients already within normal range.
Adult:
2 capsules or 3 chew tabs daily.
Children:
Not applicable.
How Supplied:
Caps—60
Chew tabs—90
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored
Sign Up for Free e-newsletters
Check out what's trending
CME Focus
Tardive Dyskinesia Clinical Commentary
CME
1.00 Credits
Breaking the Vaccination Barrier in Adults
CME|CE
1.25 Credits